etiology. Hypertrophic cardiomyopathy is associated with the extensive genetic heterogeneity (>1400 mutations in 11 or more genes) and with the high frequency of private mutations. 1, 4 Mutations in several sarcomeric and non-sarcomeric genes which may affect the morphology and functions of the heart 5, 6 are considered to be the main causes of disease. The set of the candidate pathogenic cardiomyopathy genes has been successfully identified, but the knowledge of the full genetic background and the etiopathology of primary hypertrophic cardiomyopathy remains incomplete. 7 The most affected are genes encoding cardiac myosin binding protein C (MYBPC3), cardiac β-myosin heavy chain (MYH7), and cardiac troponin isoforms I (TNNI3) and T (TNNT2). 8 The role of other sarcomeric and non-sarcomeric genes is reevaluated. 9 In fact, pathogenic sequence variants are not identified in all sporadic and familial cases.
On the other hand, some patients with hypertrophic cardiomyopathy carry more than one causative mutation in the same gene or in different genes which may be a potential factor of hypertrophic cardiomyopathy severity. 10 A precise definition of the genetic causes of hypertrophic cardiomyopathy is necessary, whereas it can improve the diagnosis and clin- 
| PATIENTS AND METHODS

| Demographic and clinical characteristics of patients
The study population consisted of 23 hypertrophic cardiomyopathy patients (13 men and 10 women), with a mean age of 58.09±15.82 years. The total number of controls enrolled in our study was 25 healthy probands of similar age and gender, all recruited from 
| Data analysis
Sequencing was performed by using 24 capillaries 3500xL Genetic Several free online tools (Mutation Taster, PhD-SNP, Polyphen2, PredictSNP, SIFT, and SNAP2) were applied in order to assess sequence-and structure-based features.
| RESULTS
The selected exons were amplified and sequenced as candidates for hypertrophic cardiomyopathy by using DNA samples from 23 patients Table 2 .
To be more precise, we detected only single nucleotide changes.
Four of identified sequence variants were predicted to be synonymous, while 38 sequence variants were missense alterations disrupting Finally, by comparing our data with Ensembl database (www.ensembl.org) we identified two variants, from the total number of 43 variants, which were previously associated with cardiomyopathy phenotype (rs730880758; rs121913629). genetic alterations for faster diagnosis of hypertrophic cardiomyopathy are not defined. A large number of mutations were detected in genes, mostly encoding sarcomeric proteins. 5, 6 Pathogenic variants in these genes were identified in multiple studies, which provided definitive evidence of disease association for these genes. However, non-sarcomeric genes can be equally responsible for the number of hypertrophic cardiomyopathy cases. 12 There is a tendency of reevaluation of the role of non-sarcomeric genes in hypertrophic cardiomyopathy etiopathogenesis. 13 In this study, we analyzed selected exons of sarcomeric and non-sarcomeric genes with the purpose to identify genetic variants with pathogenic potential in hypertrophic cardiomyopathy patients from Eastern Slovakia. The sequence variants identified in this study may be further investigated in order to elucidate molecular genetic mechanisms of hypertrophic cardiomyopathy and improve the management, diagnosis, and treatment of Slovak patients and high-risk relatives with hypertrophic cardiomyopathy.
| DISCUSSION
The Sanger sequencing approach applied in our study identified 
17-20
A large portion of patients harbors multiple sequence variants. It is assumed that the presence of multiple mutations might be a marker of disease severity. 21 The most frequently detected combination of In conclusion, the findings of our study indicate that the Sanger sequencing method is a useful approach for the identification of potentially pathogenic sequence variants associated with hypertrophic cardiomyopathy, and our results may be beneficial in the risk evaluation of individuals with disease diagnosis or with possible susceptibility to develop hypertrophic cardiomyopathy.
| CONCLUSION
The aim of the study was to analyze selected exons of sarcomeric and non-sarcomeric genes with the purpose to identify potentially pathogenic genetic variants in the patients with hypertrophic cardiomyopathy from Eastern Slovakia. In our study 43 sequence variants, due known and novel were detected. From the total number of variants identified in each analyzed exon, 11 were predicted to be potentially pathogenic, but we did not observe any strong mutation hotspot. The results of this study emphasize the importance of the whole-genome sequencing approaches in hypertrophic cardiomyopathy etiology investigations. The sequence variants identified in this study might be further investigated in order to improve the management, diagnosis, and treatment of Slovak patients with hypertrophic cardiomyopathy.
